Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01759914
Other study ID # YM076710
Secondary ID
Status Terminated
Phase N/A
First received December 30, 2012
Last updated March 6, 2014
Start date September 2012
Est. completion date July 2013

Study information

Verified date March 2014
Source University Hospitals Coventry and Warwickshire NHS Trust
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
Study type Observational

Clinical Trial Summary

Ocular hypertension and glaucoma are eye conditions associated with abnormally high fluid pressure in the eye (called intraocular pressure or IOP). If left untreated, the elevated IOP may eventually cause damage to the nerve of the eye and potential impairment of vision.

The use of certain drugs has been identified as a risk factor for raised IOP, including various forms of administration of corticosteroids. Corticosteroids can also lead to cataract, which is clouding of the lens in the eye that can affect vision.

In this research study, we would like to find out whether the use of corticosteroids in our dermatology clinic leads to raised IOP, in order to identify patients at risk and to allow them to be more closely monitored than others. It is important to identify those patients who have a corticosteroid-induced pressure rise early enough to prevent them from permanent glaucomatous visual loss.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date July 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients on whom corticosteroid treatment is being introduced for a duration of at least 12 weeks

Exclusion Criteria:

- pregnant women

- patients already under glaucoma treatment

- patients unable to give informed written consent or those unable to cooperate fully with the assessments

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Potent topical steroid

Superpotent topical steroid


Locations

Country Name City State
United Kingdom University Hospitals Coventry and Warwickshire NHS Trust Coventry West Midlands

Sponsors (2)

Lead Sponsor Collaborator
University Hospitals Coventry and Warwickshire NHS Trust University Hospital, Geneva

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in intraocular pressure from baseline Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids. after 1, 2 and 3 months No
Secondary Whether there is any clinical evidence of cataract at the final visit of the study. Measurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids. After 1, 2 and 3 months No